GenCirq

GenCirq is a synthetic biology company developing a platform for the programmable delivery of cancer therapeutics using engineered bacteria. The company's core technology, the Synchronized Lysis Circuit (SLC), allows for the periodic and localized release of therapeutic payloads directly within the tumor microenvironment. By leveraging the natural ability of certain bacteria to selectively colonize solid tumors, GenCirq aims to deliver potent drugs, such as checkpoint inhibitors and toxins, with high precision. This approach is designed to enhance therapeutic efficacy while significantly reducing the systemic side effects typically associated with conventional cancer treatments. The company is currently advancing its platform through pre-clinical development for various solid tumor indications.